Inactive Instrument

US Rare Earth Minerals Inc Stock Other OTC

US9034101082

Biotechnology & Medical Research

End-of-day quote Other OTC
- ^USD	-

Aug. 14	Bioxytran, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Aug. 11	Bioxytran Reports Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy Patient Treated with PLICID	CI

Valuation: US Rare Earth Minerals Inc

Market Cap	2.68M 2.3M 2.16M 1.97M 3.73M 256M 3.74M 25.59M 9.92M 129M 10.08M 9.86M 428M	P/E 2024	-5.27x	P/E 2025	-3.28x
Enterprise Value	3.42M 2.94M 2.76M 2.52M 4.76M 327M 4.78M 32.65M 12.65M 165M 12.86M 12.58M 546M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	99.38%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Latest news : US Rare Earth Minerals Inc

Aug. 14	Bioxytran, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Aug. 11	Bioxytran Reports Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy Patient Treated with PLICID	CI
Aug. 04	Bioxytran, Inc. and University Of Minnesota Department Of Chemistry Execute Second Sponsored Research Agreement To Advance ASI-Powered Carbohydrate Drug Design Platform	CI
Jul. 30	US officials pressed China on rare earths, farm goods commitments, Bessent says	RE
Jul. 29	Bioxytran Announces Publication of Corporate Research Report Discussing Prolectin-M Phase 2 Results, Planned 408-Patient Registrational Trial, Bxt-25 Oxygen-Therapeutic Platform, and A-Suqar Commercial Distribution Agreement	CI
Jul. 16	Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst	RE
May. 15	Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 15	Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Apr. 14	Bioxytran, Inc. Auditor Raises 'Going Concern' Doubt	CI
Mar. 17	Bioxytran, Inc. announced that it has received $1.158942 million in funding	CI
Mar. 04	Bioxytran Inc Announces Positive Dose Optimization Results And Advances Toward Phase 3 Registrational Trial For ProLectin-M	CI
Mar. 02	Bioxytran Inc reports positive phase 1b/2a clinical study results for Prolectin-M, broad-range antiviral drug in mild to moderate Covid-19	RE
Feb. 17	Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical Ltd for A-SUQAR Dietary Supplement	CI

More news

Press Releases: US Rare Earth Minerals Inc

Aug. 11	Bioxytran Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID, a Novel Galectin Antagonist Designed with Artificial Intelligence	AQ
Aug. 04	Bioxytran Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis Drugs	AQ
Jul. 29	Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research	AQ
May. 29	Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25	AQ
Mar. 20	BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT	AQ

More press releases

Managers and Directors: US Rare Earth Minerals Inc

Manager	Title	Age	Since
David Platt CEO	Chief Executive Officer	73	2018-08-31
Ola Soderquist DFI	Director of Finance/CFO	65	2018-08-31
Leslie Ajayi CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Dale Conaway BRD	Director/Board Member	71	2018-11-01
Alan Hoberman BRD	Director/Board Member	73	2018-11-01
David Platt CHM	Chairman	73	2018-08-31

More insiders

Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with intended applications, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.

Employees

Sector

Biotechnology & Medical Research

More about the company

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

The best tools reserved for subscribers to boost the performance of your investments!

Maximize my profits

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+3.31%	-3.70%	+61.03%	+103.64%	71.35B
ARGENX SE	+2.09%	+2.28%	+49.95%	+91.14%	64.17B
BIONTECH SE	-1.62%	-0.59%	+7.31%	-6.82%	28.65B
INSMED INCORPORATED	+0.50%	-4.08%	-5.18%	+479.69%	27.06B
WUXI BIOLOGICS (CAYMAN) INC.	-2.78%	+4.47%	+52.49%	+14.43%	27.33B
GENMAB A/S	-1.68%	+0.33%	+36.86%	-17.91%	20.47B
PHARMAESSENTIA CORPORATION	+1.02%	+6.43%	+269.42%	+420.34%	19.36B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-0.57%	-4.06%	+10.79%	+515.61%	15.96B
EXELIXIS, INC.	-0.06%	+4.58%	+48.36%	+156.45%	14.05B
Average	+0.05%	+4.46%	+59.01%	+195.18%	32.04B
Weighted average by Cap.	+0.85%	+3.31%	+55.08%	+154.72%

	2024	2025
Net sales	-	-
Net income	-2.37M -2.03M -1.91M -1.74M -3.29M -226M -3.3M -22.56M -8.74M -114M -8.89M -8.69M -377M	-2.12M -1.82M -1.71M -1.56M -2.95M -202M -2.96M -20.24M -7.84M -102M -7.97M -7.8M -338M
Net Debt	1.09M 935K 877K 801K 1.51M 104M 1.52M 10.38M 4.02M 52.4M 4.09M 4M 174M	741K 636K 597K 545K 1.03M 70.65M 1.03M 7.06M 2.74M 35.64M 2.78M 2.72M 118M

US Rare Earth Minerals Inc Stock Other OTC

Stocks

US9034101082

Biotechnology & Medical Research

Valuation: US Rare Earth Minerals Inc

Latest news : US Rare Earth Minerals Inc

Press Releases: US Rare Earth Minerals Inc

Managers and Directors: US Rare Earth Minerals Inc

Bio Therapeutic Drugs

Financials

Company Profile